Skip to main content

COVID-19 Topic Center

Issue Features

Cover Story
While the COVID-19 pandemic has resulted in increased morbidity and mortality rates on a global scale, it has also exacerbated and brought the mental health crisis to the forefront. More than ever, people are seeking mental health services and experts believe a population-based approach could be…
Feature
As COVID-19 spurs expansion of payer telehealth offerings, some say initiatives begun during the pandemic could become the norm.
Feature
The American Rescue Plan recently signed into law includes an incentive to encourage states to expand Medicaid. Will any of the 12 holdout states broaden their program for the needy, or do political divisions run so deep that compromise is out of the question?
Cover Story
What does this say about the affordability of health care, and are there solutions to minimize reliance on this ubiquitous tool?
Feature
As the COVID-19 pandemic continues to stretch the ability and capacity of health care systems—from curbing infection rates, treating severe illness, understanding new variants, to distributing and administering limited vaccine doses—gaps and vulnerabilities within those same systems continue to…
Feature
What will the new president do with the Most Favored Nation rule he inherits from the departing administration; what other drug price initiatives are in the offing; and how should managed care stakeholders prepare?
This special section of First Report Managed Care includes data on the new molecular entities and new therapeutic biological products approved by the US Food & Drug Administration’s Center for Drug Evaluation and Research in 2020. This part 1 page includes approvals in dermatology,…
This special section of First Report Managed Care includes data on the new molecular entities and new therapeutic biological products approved by the US Food & Drug Administration’s Center for Drug Evaluation and Research in 2020. This part 2 page includes approvals in  oncology, ophthalmology…
Cover Story
In what seems like an eleventh-hour maneuver, the Trump administration moves forward implementing its latest drug pricing model. However, experts say it is fraught with complications and may get tied up in the courts. Our panel sorts through the issue and advises how stakeholders should prepare.
Feature
The end of the year is fast-approaching and with it comes several strides in the development of vaccinations for COVID-19, but there are still many hurdles to overcome.
Back to Top